Description:LEE011 Succinate, also known by its chemical name as a selective inhibitor of cyclin-dependent kinases (CDKs), particularly CDK4 and CDK6, is a compound that has garnered attention in cancer research. It is primarily studied for its potential therapeutic effects in treating various malignancies, including breast cancer and other tumors characterized by dysregulated cell cycle progression. The succinate form indicates that it is a salt or ester derived from succinic acid, which may enhance its solubility and bioavailability. LEE011 functions by disrupting the phosphorylation of retinoblastoma protein, thereby inhibiting cell cycle progression from the G1 to the S phase, leading to reduced proliferation of cancer cells. Its pharmacokinetic properties, including absorption, distribution, metabolism, and excretion, are crucial for determining its efficacy and safety profile in clinical settings. As with many investigational drugs, ongoing studies are essential to fully elucidate its mechanism of action, optimal dosing regimens, and potential side effects in patients.
We use cookies to enhance your visit. We do not include advertising.
Please see our Cookies Policy for more details or adjust your preferences in "Settings".
This is the advanced settings system for our own and third-party cookies. Here you can modify parameters that will directly affect your browsing experience on this website. If you wish you may check the list of Cookie types.
Please note that disabling cookies can cause failures in the normal operation of the web.